F Haroun, MD

828 posts

F Haroun, MD banner
F Haroun, MD

F Haroun, MD

@Cancer_talks

👨‍🏫 Hematology & Oncology University of Minnesota (previously at GWU). Thoracic and Head&Neck cancer.

Minneapolis, MN Katılım Nisan 2016
801 Takip Edilen766 Takipçiler
F Haroun, MD
F Haroun, MD@Cancer_talks·
Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Wisconsin gotoper.com/courses/commun…
English
0
0
0
37
F Haroun, MD retweetledi
GW Cancer Center
GW Cancer Center@GWCancer·
Sonal Paul, MD, Joins the George Washington University Cancer Center as a Hematologist-Oncologist Welcome to GW Cancer Center, Dr. Paul! bit.ly/3x629E5
GW Cancer Center tweet media
English
0
1
2
316
F Haroun, MD
F Haroun, MD@Cancer_talks·
Immensely proud of our GW #hemonc fellows. Humbled by their maturity and professionalism, and confident that they will provide patients with the most compassionate and informed care. #graduation @GW_MFA @GWCancer @GWSMHS This group would make any PD proud!
F Haroun, MD tweet mediaF Haroun, MD tweet media
English
0
3
17
1.6K
F Haroun, MD
F Haroun, MD@Cancer_talks·
Durvalumab consolidation for pts with limited-stage small-cell lung ca Spigel #lcsm #asco24 The poor prognosis of SCLC even in limited stg disease translated to an OS benefit in the #ADRIATIC mirroring the CASPIAN results. Different SEA similar wave with 10% absolute OS benefit
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
0
1
5
894
F Haroun, MD
F Haroun, MD@Cancer_talks·
Osimertinib after def CRT in pts with unresectable stg III EGFRm NSCLC phase 3 LAURA stud: Suresh Ramalingam Impressive PFS benefit with Osi is not a surprise. High recurrence rates drive the benefit- delay in recurrence is a clinically sign, PFS ≠ OS ≠ cure #Lcsm #asco24
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
1
1
1
420
F Haroun, MD
F Haroun, MD@Cancer_talks·
Neoadjuvant nivo plus ipi versus adj nivo in macro, resectable st Ill #melanoma: The phase 3 #NADINA trial #asco24 Dr.Blank Impressive PFS benefit of 2 cycles of neoadjuvant vs a standard of care adj approach. Benefit shorter duration of therapy Negative more iAE with CTLA4
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
0
5
7
1.7K
F Haroun, MD
F Haroun, MD@Cancer_talks·
Amivantamab plus lazertinib vs osimertinib in 1st line EGFR-mu advanced NSCLC with high-risk disease 2ndary analysis of phase 3 MARIPOSA Dr.Enriqueta Felip PFS HR 0.7 High risk: brain met (41%), Liver met at baseline (16%), Detectable baseline cDNA by NGS° (85%) TP53 co-mu (54%)
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
1
0
2
391
F Haroun, MD
F Haroun, MD@Cancer_talks·
CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC - 5-Year Follow-Up At 5yrs PFS: Lorlatinib 60% (5-yr) vs Crizotinib 8% Lorlatinib IC DFS >93% with HR0.03 Grade 3/4 AEs: 77% Lorlatinib vs 57% Crizotinib #asco24 #lcsm
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
0
0
1
319
F Haroun, MD
F Haroun, MD@Cancer_talks·
Sacituzumab tirumotecan (SKB264/ MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase Il OptiTROP-Lung01 study. Wenfeng Fang, MD, PhD
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
0
0
2
576
F Haroun, MD
F Haroun, MD@Cancer_talks·
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in pts with previously treated NSCLC with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. #DavidPlanchard #asco24 #lcsm
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
0
1
2
558
F Haroun, MD
F Haroun, MD@Cancer_talks·
Sacituzumab govitecan (SG) vs docetaxel in pts with mNSCLC previously treated with platinum chemo and PD(L)-inhibitors Primary results from the phase 3 EVOKE-01 study OS- no benefit- subgroup may show benefit in patient without a prior response to PD inhibition. #asco24 #lcsm
F Haroun, MD tweet mediaF Haroun, MD tweet mediaF Haroun, MD tweet media
English
0
0
2
281
F Haroun, MD
F Haroun, MD@Cancer_talks·
Back in Chicago for ASCO, excited to see that breakthroughs in lung cancer are dominating the meeting. #asco #asco2024 #lcsm
F Haroun, MD tweet media
English
0
4
19
2.1K
F Haroun, MD retweetledi
Charbel Matar
Charbel Matar@Charbel_matar1·
Thrilled to be part of this amazing talented group of featured voices #ASCO2024 for the third year 🎉 Follow the team for more insight on the most updated conference in Oncology 2024. @HamidMD10 @jacobadashek @TwoOncDocs @DarcyBurbage @fumikochino @DevikaDasMD @ADesaiMD
ASCO@ASCO

Announcing the 2024 ASCO Annual Meeting Featured Voices! Follow along for a range of expert insights & join the discussion using the official hashtag: #ASCO24 ⤵️

English
3
4
34
5.4K
F Haroun, MD
F Haroun, MD@Cancer_talks·
I welcome the +ve #LAURAIII trial for #Osimertinib post ChemoRT in locally advanced EGFRm NSCLC despite the indefinite indication/design Cure in stage III NSCLC continues to be the aim but isn’t the norm Longterm DFS (🫣OS trend) is a huge step forward. astrazeneca.com/media-centre/p…
English
0
0
0
246

Keşfet

@appos @GW_MFA @GWCancer @GWSMHS @ASCO @RamalingamMD @OncoAlert @FordePatrick